Agilent Technologies Inc. has announced the shipping of a new instrument that offers laboratories a more affordable, low-throughput option for analyzing the quality of RNA and DNA samples.
Founded in 1999, headquartered in Santa Clara, California, Agilent Technologies Inc. is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,300 people worldwide.
The new system provides automated electrophoresis and extends the company’s ScreenTape technology to smaller biobanks that need to provide information about sample integrity. The 4150 TapeStation system is compatible with Agilent’s complete portfolio of all DNA and RNA assays which also run on the higher throughput 4200 TapeStation instrument.
“The Agilent 4150 TapeStation system makes quality control in next-generation sequencing easier, faster, and more economical than ever.” … “Laboratories that have limited budgets will now be able to take advantage of all the features and benefits of our ScreenTape technology: ease of use, constant cost per sample, fast and accurate results, and minimal hands-on time,” – Knut Wintergerst, general manager of Agilent’s Biomolecular Systems and Solutions product line